Ultrahypofractionated vs hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: a systematic review and meta-analysis of phase III randomized trials

In 2019, approximately 174,650 men will be diagnosed with prostate cancer in the United States.[1] Recent estimates have demonstrated that number to be more than twofold higher in Europe.[2] The Prostate Testing for Cancer and Treatment (ProtecT) trial suggested that conventionally fractionated radiation therapy (CFRT) (1.8-2 Gy, 5 days per week, for 8-9 weeks to a total dose of 70-81 Gy) offers similar oncologic outcomes with improved quality of life when compared to radical prostatectomy.[3,4] Projections indicate that more than one third of men with localized cancer of the prostate in the United States receive some form of radiation therapy (RT).
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research